Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novartis AG : The stock approaches again the support level

06/16/2020 | 03:37am EST
long trade
Stop-loss triggered
Entry price : 82.07CHF | Target : 88CHF | Stop-loss : 77.8CHF | Potential : 7.23%
Shares in Novartis AG are retreating towards the lower bound of a horizontal trading range. Investors could use the proximity of this support area to initiate new long positions.
Investors have an opportunity to buy the stock and target the CHF 88.
Novartis AG : Novartis AG : The stock approaches again the support level
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • The company has solid fundamentals for a short-term investment strategy.

  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.

  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
  • With an enterprise value anticipated at 3.91 times the sales for the current fiscal year, the company turns out to be overvalued.

© MarketScreener.com 2020

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (USD)
Sales 2021 52 431 M - -
Net income 2021 9 990 M - -
Net Debt 2021 25 824 M - -
P/E ratio 2021 20,3x
Yield 2021 3,53%
Capitalization 213 B 213 B -
EV / Sales 2021 4,55x
EV / Sales 2022 4,17x
Nbr of Employees 105 794
Free-Float 86,4%
Upcoming event on NOVARTIS AG
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 109,68 $
Last Close Price 94,24 $
Spread / Highest target 58,0%
Spread / Average Target 16,4%
Spread / Lowest Target -4,50%
EPS Revisions
Managers and Directors
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Elizabeth Theophille Chief Technology & Digital Officer
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG0.20%212 810
JOHNSON & JOHNSON6.67%441 951
ROCHE HOLDING AG3.62%309 011
PFIZER INC.-1.55%201 436
MERCK & CO., INC.-5.78%194 990